Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nice job mods,
you've had five full days to request a name and ticker change while your stock has been trading under the wrong ticker/name than your message board reflects and the rest of the market recognizes for two full days.
It took a non-stock holder to do your job.
PlasmaTech Biopharmaceuticals Announces Name Change to Abeona Therapeutics to Reflect Broader Rare Disease Commitment - MarketWatch
http://www.marketwatch.com/story/plasmatech-biopharmaceuticals-announces-name-change-to-abeona-therapeutics-to-reflect-broader-rare-disease-commitment-2015-06-19-8173331
.
PlasmaTech Biopharmaceuticals Announces Name Change to Abeona Therapeutics to Reflect Broader Rare Disease Commitment
ABEO
NEWS POSTED ON SCOTTRADE Roth Capital initiated coverage on Plasmatech Biopharmaceuticals Inc (NASDAQ: PTBI) with a Buy rating. The target price for Plasmatech is set to $16. Plasmatech shares have dropped 55.81 percent over the past 52 weeks, while the S&P 500 index has surged 9.07 percent in the same period. Plasmatech shares rose 12.45 percent to $7.95 in pre-market trading. View More Analyst Ratings for PTBIView the Latest Analyst Ratings Write to editorial@benzinga.com with any questions about this content. Subscribe to Benzinga PRO: http://pro.benzinga.com 2015 Benzinga Newswires. Benzinga does not provide investment advice. All rights reserved. Acquire Media
Really that's why it's up. I dont see on Yahoo.
Showing on Scottrade via Dow Jones News
Roth initiated coverage of the company with a BUY rating and a 12 month price target of $16.
Where? Thx,
Will $8 pre market support hold. Seems to be bouncing off that for a bit now.
Is the float really 4.6 million shares?
Boom again.....
LMAO @ twits shorts, sky is falling....no more! PTBI
$PTBI Weekly Chart - the 50 DMA @ 8.40 is the Key level to turn into support - to keep it simple - candles forming below the 50 day simple moving average = downside risk & candles forming above the 50 DMA = upside potential -
very light volume pullback this week compared to the last 3 weeks of monster volume - RSI & Fast Sto are in the above 50 bull zone -
Nice and slow dawg.
Wouldn't you after making over 100%++
They'll buy back in higher when things are about to move.
I'm surprised they just didn't hold them and sell em to shorts. Isn't that what most tutes do anyway?
Looks like some funds are liquidating their positions
$PTBI recent news/filings
bullish
high and tight flag breakout
reference
http://thepatternsite.com/htf.html
## source: finance.yahoo.com
Wed, 27 May 2015 12:03:00 GMT ~ PlasmaTech Biopharmaceuticals to Present at the 2015 Marcum MicroCap Conference
[Marketwired] - PlasmaTech Biopharmaceuticals, Inc. , a biopharmaceutical company focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, announces today ...
read full: http://finance.yahoo.com/news/plasmatech-biopharmaceuticals-present-2015-marcum-120300443.html
*********************************************************
Tue, 26 May 2015 17:15:39 GMT ~ REMINDER: PlasmaTech Biopharmaceuticals First Quarter 2015 Conference Call Tomorrow
[Marketwired] - PlasmaTech Biopharmaceuticals, Inc. , a biopharmaceutical company focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, will provide ...
read full: http://finance.yahoo.com/news/reminder-plasmatech-biopharmaceuticals-first-quarter-171539579.html
*********************************************************
Fri, 22 May 2015 17:04:22 GMT ~ PLASMATECH BIOPHARMACEUTICALS INC Financials
read full: http://finance.yahoo.com/q/is?s=ptbi
*********************************************************
Wed, 20 May 2015 12:03:00 GMT ~ PlasmaTech Biopharmaceuticals Announces Orphan Drug and Rare Pediatric Disease Designations From FDA
[Marketwired] - PlasmaTech Biopharmaceuticals, Inc. , a biopharmaceutical company focused on gene therapy and plasma-based products for severe and life- threatening rare diseases announced today that the U.S. Food and ...
read full: http://finance.yahoo.com/news/plasmatech-biopharmaceuticals-announces-orphan-drug-120300783.html
*********************************************************
Mon, 18 May 2015 20:32:40 GMT ~ PLASMATECH BIOPHARMACEUTICALS INC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Unregistere
read full: http://biz.yahoo.com/e/150518/ptbi8-k.html
*********************************************************
$PTBI charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$PTBI company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/PTBI/company-info
Ticker: $PTBI
OTC Market Place: Not Available
CIK code: 0000318306
Company name: PlasmaTech Biopharmaceuticals, Inc.
Company website: http://www.accesspharma.com
Incorporated In: DE, USA
Business Description: Access Pharmaceuticals, Inc. is an emerging pharmaceutical company focused on the development and commercialization of proprietary products for the treatment and supportive care of cancer patients. Access has one approved product, two products in Phase 2 development, and five preclinical development programs. The company's approved product is MuGard(TM) for the management of oral mucositis (a common and debilitating side effect of many cancer therapies) for which marketing authorization has been allowed by the FDA. Access' ProLindac(TM), a polymer-linked platinum cancer drug is in Phase 2 clinical testing in cancer patients, as is Phenylbutyrate, a pleotropic agent which current evidence suggests acts as both an HDAC inhibitor and a differentiating agent. The Company's preclinical development programs include Angiolix, a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is potentially targeted to a number of tumor types, including breast and ovarian; Prodrax, a non-toxic prodrug which is activated in the hypoxic zones of solid tumors to kill tumor cells; Alchemix, a chemotherapeutic agent that combines two modes of action to overcome drug resistance, and oral insulin, which utilizes the company's Cobalamin(TM) oral drug delivery technology.Less >>
$PTBI share structure
## source: otcmarkets.com
Market Value: $179,699,321 a/o May 26, 2015
Shares Outstanding: 19,988,801 a/o Mar 30, 2015
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.01
$PTBI extra dd links
Company name: PlasmaTech Biopharmaceuticals, Inc.
Company website: http://www.accesspharma.com
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/PTBI/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/PTBI/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=PTBI+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=PTBI+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=PTBI+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/PTBI/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/PTBI/news - http://finance.yahoo.com/q/h?s=PTBI+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/PTBI/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/PTBI/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/PTBI/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/PTBI/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/PTBI/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/PTBI/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/PTBI/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/PTBI/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=PTBI+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/PTBI
DTCC (dtcc.com): http://search2.dtcc.com/?q=PlasmaTech+Biopharmaceuticals%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=PlasmaTech+Biopharmaceuticals%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=PlasmaTech+Biopharmaceuticals%2C+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.accesspharma.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.accesspharma.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.accesspharma.com
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/PTBI/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/PTBI
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/PTBI/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/PTBI/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/PTBI/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000318306&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/PTBI/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/PTBI/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/PTBI/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/PTBI/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=PTBI&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=PTBI
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/PTBI/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=PTBI+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=PTBI+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=PTBI
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=PTBI
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=PTBI+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/PTBI/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=PTBI+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/PTBI.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=PTBI
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/PTBI/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/PTBI/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/PTBI/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/PTBI/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/PTBI
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/PTBI
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/PTBI:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=PTBI
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=PTBI
$PTBI DD Notes ~ http://www.ddnotesmaker.com/PTBI
SA transcript of today's earnings conference call for any of you that might actually be interested.
http://seekingalpha.com/article/3215446-plasmatech-biopharmaceuticals-ptbi-ceo-tim-miller-on-q1-2015-results-earnings-call-transcript?page=4&p=qanda&l=last
Cc just started
Let's see what she does. I would have at least taken half off at any kind of profit or break even point.
Keep it on topic ......PTBI
I got in at 3.20 and bought more at 2.80. Anyone of jbems list still holding on to this one?
CC is tomorrow at 10am eastern
Jya just have to love all this cash coming in. Should be helpful pushing their trials forward. Not to mention the revenues that should begin to come in from MuGard.
Probably why they kept the price under $9
Looks like they had a small $10,000,000 offering
Yeah I was thinking about that
I'm still waiting on my apology. Stock performing as I thought it would which is why I gave the advice I gave Monday...
It's coming back
Well I agree with you on the heavy shorting part. Take a look at L2...
Did you buy @ $3?
Disclosure, I hope you did.....
LMAO
shorts love ya.....
disclosure, lmao
Traders blog has post, that there is corrupted naked shorting hitting the stock by the pro hedge funds that are stil short, and want to close out that position and go long, before the rumor of a big Wall Street house is about to upgrade it with a $21.00 price target.
Correct, just orphan drug status approved. Prior poster evidently couldn't read beyond the headline, or was being deliberately deceptive.
Is it still big news? That's a matter or perception, although it doesn't seem to matter to those currently posting on the board. Sanfilippo Syndrome A and B are rare childhood diseases and the programs haven't progressed beyond animal testing to date. Human clinical testing isn't scheduled to start till later this year, so it's likely at least a couple of years away until PBTI could apply for FDA approval for people.
Does that justify this kind of excitement? Doubtful (IMO), but nothing seems to matter to those currently trading the stock except the action. Reminds me of watching a school of piranha's attaching a piece of bloody meat thrown in the water. Interesting to watch, but what happens once the meat is gone? They go to look for a new food source elsewhere.
Disclosure, watching but have no position in the stock.
Next leg up to over $10.85 could spike it up to over $11.00 as it freaks out a lot more of this mornings corrupted shorts who were trying to get it sell off, and are now trapped and about to get blown out deep in the red.
News is on DJNW , has not hit many other sources yet.
Dip and RIP!!!!!!! PTBI sweetness!!!!
News has not hit IHUUB, MARKETWIRE, ETC.
Looking for a lite bottom here then back over 10 lots bought I the 10's
I think they only received orphan drug status not approved yet. It's still big news though.
New news out! FDA approves their orphan drug! This should skyrocket today
Followers
|
54
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1251
|
Created
|
02/13/07
|
Type
|
Free
|
Moderators |
Abeona Therapeutics Announces Fourth Quarter and Full Year 2015 Summary Financial Results and Recent Operational Highlights |
NEW YORK, NY and CLEVELAND, OH -- (Marketwired) -- 03/08/16 -- Abeona Therapeutics, Inc. (NASDAQ: ABEO), a biopharmaceutical company focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, today announced summary financial results for the fourth quarter and full fiscal year ended December 31, 2015. The Company will provide a business update for investors and other stakeholders on a conference call, Wednesday, March 9th, at 4:45 pm (Eastern). Tim Miller, Ph.D., President and CEO and Jeffrey Davis, Chief Operating Officer, together with other executives, will conduct the call. Interested parties are invited to participate in the call by dialing 877-269-7756 (toll free domestic) or 201-689-7817 (international). The call will consist of an overview of the Company's 4Q15 financials, and a discussion of business highlights. "The past year has led to significant advancements in our goal of building a leadership position in the field of gene therapy and plasma protein therapies towards transforming the lives of patients with rare diseases," stated Steven H. Rouhandeh, Executive Chairman. "In 2015, we expanded our pipeline with two clinical stage AAV gene therapies for Sanfilippo syndrome types A and B, added a third AAV gene therapy product in Juvenile Neuronal Ceroid Lipofuscinosis (JNCL) (also known as juvenile Batten disease), signed a license to an innovative CRISPR-Cas9 gene editing platform in rare blood disorders, with an initial focus in Fanconi anemia, strengthened our team, and added substantial financial resources to our balance sheet. In 2016, our priorities include driving our AAV gene therapy and alpha-1 protease inhibitor programs into the clinic, and advancing our gene editing programs including defining of regulatory pathways to bring our CRISPR product candidates to patients." Tim Miller, Ph.D., President and CEO, stated, "2016 will be an exciting, transformative year for Abeona Therapeutics as we position ourselves to enter multiple human clinical trials with our pipeline of innovative product candidates. As recently announced, the FDA allowance of the IND for the Phase 1/2 clinical study of ABO-102 for patients with Sanfilippo syndrome type A (MPS IIIA) moves our programs into the clinic here in the US, and we look forward to working with our collaborators to expand this program into Europe and Australia later this year. We believe that our gene therapy programs in Sanfilippo syndrome type B (ABO-101) and Juvenile Neuronal Ceroid Lipofuscinosis (ABO-201) will follow shortly. Lastly, we would like to thank our dedicated researchers and clinical collaborators, as well as the many dedicated patient foundations, for their tireless efforts and commitment to advancing new treatment options for these devastating unmet medical needs." Recent Abeona Highlights
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |